Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04424355 |
Recruitment Status :
Recruiting
First Posted : June 9, 2020
Last Update Posted : December 10, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Coronavirus Infections Pneumonia | Diagnostic Test: Chest MRI |
Currently, with increased load of CT studies, alternative methods of viral pneumonia signs' visualization are required.
Investigators hypothesize that chest MRI could be a test for detecting pulmonary features of COVID-19. They consider using MRI to assess COVID-19 viral pneumonia. Absence of radiation exposure to patients is a clear advantage of MRI.
This is a prospective, observational cohort study assessing patients with suspected COVID-19. It's primary goal is to determine the ability of multiparametric MRI to detect lung abnormalities - ground-glass opacity (GGO), consolidation, "crazy paving" pattern, pleuritis - in comparison to CT scan. In this study each patient with suspected pneumonia will sequentially undergo both chest CT and MRI during his/her visit. Scan protocols will be identical for each patient. Each participants completed an online questionnaire.
Study Type : | Observational |
Estimated Enrollment : | 115 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Possibilities of Chest Magnetic Resonance Imaging (MRI) in Diagnostics of COVID-19. The Use of MRI to Assess Lung Damage in Patients With Coronavirus Infection |
Actual Study Start Date : | May 19, 2020 |
Estimated Primary Completion Date : | July 19, 2021 |
Estimated Study Completion Date : | December 20, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Patients with suspected pneumonia COVID-19
Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, "crazy paving" pattern, pleuritis.
|
Diagnostic Test: Chest MRI
Patients referred by the primary care physician with suspected pneumonia
Other Name: Chest CT scan |
Patients with suspected pneumonia with COVID -19
Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, "crazy paving" pattern, pleuritis.
|
Diagnostic Test: Chest MRI
Patients referred by the primary care physician with suspected pneumonia
Other Name: Chest CT scan |
- Number of zones of pulmonary parenchyma corresponding to viral pneumonia detected by chest MRI in comparison with CT scan [ Time Frame: Upon completion, up to 1 year ]Expected number - more than two zones

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- A referral from the attending physician for a chest CT scan
- Suspected pneumonia
- Signed informed consent
- Over 18 years old
Exclusion Criteria:
- Pregnant or nursing women
- Presence of foreign implanted objects in the body at the scan level (including cardiac pacemakers, spine metalware)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04424355
Contact: Olga Panina | +79266210179 | olgayurpanina@gmail.com | |
Contact: Yuri Vasilev | +79067716776 | dr.vasilev@me.com |
Russian Federation | |
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department | Recruiting |
Moscow, Russian Federation, 109029 | |
Contact: Olga Panina +79266210179 olgayurpanina@gmail.com |
Responsible Party: | Sergey Morozov, Chief Research Officer, Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department |
ClinicalTrials.gov Identifier: | NCT04424355 |
Other Study ID Numbers: |
2020-2 |
First Posted: | June 9, 2020 Key Record Dates |
Last Update Posted: | December 10, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Computed tomography Magnetic resonance imaging Lung MRI |
Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia Lung Diseases |
Respiratory Tract Diseases Respiratory Tract Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Diseases |